Results 81 to 90 of about 3,140 (170)

Enhancing Efficacy and Quality of Life in Patients with Herpes Zoster Infection in Hairy Cell Leukemia

Case Reports in Hematology
Hairy cell leukemia (HCL) is an infrequent and persistent B-cell inert lymphoid leukemia. In this study, we present the case of a 71-year-old female patient with a previous diagnosis of variant HCL who experienced a severe herpes zoster infection leading
Xiaowei Feng, Yuchen Tao, Qi Hu, Yuanxia Liu, Jizhang Bao, Wenwen Jiang   +5 more
doaj   +1 more source

Remarkable Response of Hairy Cell Leukemia Variant to Single-Agent Cladribine. [PDF]

Cureus, 2022
Otieno SB, Ogbeide O.
europepmc   +1 more source

Cytologic Characteristics of the Feline Ovary at Different Sexual Stages

Veterinary Clinical Pathology, EarlyView.
ABSTRACT Background Cytology is a valuable diagnostic tool in veterinary medicine, allowing rapid and minimally invasive diagnosis. However, its application in the reproductive tracts of small animals is limited, primarily used to assess mammary masses and stage the estrous cycle.
Alba Martí, Josep Pastor, David Prandi, Adrià Aguilar‐Catalan, Maria Montserrat Rivera del Alamo   +4 more
wiley   +1 more source

Successful treatment of hairy cell leukemia variant with obinutuzumab. [PDF]

Ann Hematol, 2022
Al-Sarayfi D, Meeuwes FO, Munnink TO, Plattel W, Rosati S, Matutes E, Nijland M.   +6 more
europepmc   +1 more source

Drafting the calmodulation playbook: Emerging structural insights into transient receptor potential channel regulation by calmodulin

The Journal of Physiology, EarlyView.
Abstract figure legend Calmodulin (CaM) is a ubiquitous calcium (Ca2+) sensor that translates intracellular Ca2+ signals into modulation of hundreds of effector proteins including ion channels. CaM is increasingly recognized as a key regulator of the transient receptor potential (TRP) channel family, yet the underlying ‘calmodulation playbook’ is only ...
Aden M. Alemayhu, Candice E. Paulsen
wiley   +1 more source

Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant. [PDF]

Onco Targets Ther, 2021
Liu Q, Harris N, Epperla N, Andritsos LA.   +3 more
europepmc   +1 more source

Complex Genetic Architecture in RASopathies: Constitutional PTPN11 and Mosaic RIT1 Pathogenic Variants Underlying Severe Noonan Syndrome With Adult‐Onset Acute Myeloid Leukemia

American Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1879-1883, August 2026.
ABSTRACT Noonan syndrome (NS) is a genetically heterogeneous disorder characterized by a broad spectrum of clinical features resulting from dysregulation of the RAS/MAPK pathway. Although complex genotypes are increasingly recognized in NS, cases harboring two distinct pathogenic variants in different NS genes remain extremely rare.
Francesco Prevedello, Dario Seif Ali, Chiara Piccolo, Chiara Rigon, Monica Forzan, Elena Tacchetto, Roberta Palmitessa, Davide Calosci, Leonardo Salviati, Carmela Gurrieri, Eva Trevisson   +10 more
wiley   +1 more source

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia-variant. [PDF]

Genes Chromosomes Cancer, 2021
Locher M, Jukic E, Bohn JP, Untergasser G, Steurer M, Cramer CA, Schwendinger S, Vogi V, Verdorfer I, Witsch-Baumgartner M, Nachbaur D, Gunsilius E, Wolf D, Zschocke J, Steiner N.   +14 more
europepmc   +1 more source

Hairy Cell Leukemia Variant Developing in a Background of Polycythemia Vera

Archives of Pathology & Laboratory Medicine, 2003
Abstract We report a case of hairy cell leukemia variant developing in a background of polycythemia vera in a 77-year-old man who presented with lymphocytosis and splenomegaly. Classic hairy cell leukemia in a patient with polycythemia vera has been reported previously, but hairy cell leukemia variant arising in a patient with ...
Nadine P, Kelly, Serhan, Alkan, Sucha, Nand   +2 more
openaire   +2 more sources

Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma.
Shen Li, Alexandra E. Rojek, Reid Shaw, Cristina O’Donoghue, J. Michael Millis, Daniel J. Olson   +5 more
wiley   +1 more source